Twist Bioscience Begins Shipping of Synthetic RNA Controls for Kappa (B.1.617.1) SARS-CoV-2 Variants for Development of Accurate Tests

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it has started shipping its synthetic RNA reference controls for the SARS-CoV-2 Kappa (B.1.617.1) variant strain. The company is also working...

Click to view original post